Head & Neck/Thyroid Cancers
New investigational helmet device shrinks glioblastoma
A case report of a 53-year-old man describes using an “Oncomagnetic Device” that reduced the size of a tumor after one month of treatment.
Clinical Topics & News
Impact of an Oral Antineoplastic Renewal Clinic on Medication Possession Ratio and Cost-Savings
The creation of a pharmacist-managed oral antineoplstic renewal clinic resulted in an increase in the median medication possession ratio,...
Study supports intensifying chemoradiotherapy for head and neck cancer
Intensifying chemoradiotherapy appeared to improve outcomes in locally advanced head and neck cancer.
The power and promise of social media in oncology
Dr. Alan Lyss describes a recent presentation on the role of social media in oncology.
Personalized cancer vaccine shows early promise across tumor types
The vaccine consists of patient-specific synthetic neoantigen peptides and is given to patients in the adjuvant setting.
Don’t delay: Cancer patients need both doses of COVID vaccine
For patients with cancer, immune response to the first dose of the Pfizer COVID-19 vaccine is reduced, and there is a need for a booster dose at...
How has the pandemic affected rural and urban cancer patients?
Cisplatin tops cetuximab for advanced head and neck cancer
Managing cancer outpatients during the pandemic: Tips from MSKCC
MSKCC has established guiding principles on how to manage cancer patients during the pandemic.
COVID-19 vaccination in cancer patients: NCCN outlines priorities
Recommended timing of vaccination varies based on cancer and treatment type.